National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Patisiran (Onpattro®) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.


NCPE Assessment Process Ongoing
Rapid review commissioned 07/12/2018
Rapid review completed 03/01/2019
Rapid Review outcome A full HTA is recommended
Full pharmacoeconomic assessment commissioned by the HSE 09/01/2019
Pre-submission consultation with Applicant 26/02/2019
Submission received from Applicant 28/06/2019
Preliminary review sent to Applicant 18/10/2019
NCPE assessment re-commenced 15/11/2019
Preliminary review # 2 sent to Applicant 22/11/2019
NCPE assessment re-commenced 06/12/2019
Factual accuracy sent to Applicant 31/01/2020
NCPE assessment re-commenced 13/02/2020
Factual accuracy # 2 sent to Applicant 18/02/2020
NCPE assessment re-commenced 19/02/2020
NCPE assessment completed 20/02/2020
NCPE assessment outcome The NCPE recommends that patisiran (Onpattro®) is not considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.*

Technical Summary

Plain English Summary

 *This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.